Natick, Massachusetts-based biotech firm Allorion Therapeutics secured $50M in Series B funding co-led by INCE Capital and Qiming Venture Partners.
Incoming funds will enable the firm to pursue clinical trials in the
U.S. and China for its lead candidates aimed at treating oncology and
autoimmune diseases.
- In
addition, the firm will use the proceeds to identify additional
therapeutics, validate other programs, and expand its workforce.
- The Series B round brings its total funds raised to date to over $100M.
- TF Capital, Long River Investment, Octagon Capital, and Elikon Venture backed the current funding round.
- Qiming led the firm's $40M Series A funding round in November 2021.
